Vaccines for developing countries: the costs and benefits of waiving patents

There is much debate about whether the patents on COVID-19 vaccines should be waived to allow low-income countries to produce doses for themselves. The Initiative on Global Markets Forum’s survey asked European and US experts to express their views on this issue and the broader challenges of vaccinating the world. Romesh Vaitilingam sums up the results of the survey.